RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5

RBC Capital analyst Douglas Miehm has maintained a 'Sector Perform' rating on Pacira BioSciences (NASDAQ:PCRX) and raised the price target from $25 to $36.5. This adjustment reflects a positive outlook on the company's performance.